Navigating Combination Therapy and Access Challenges in ASCVD

This episode, titled 'Navigating Combination Therapy and Access Challenges in ASCVD,' features panelists discussing the practical and emotional challenges of managing cardiovascular risk in patients who feel well but carry significant underlying disease burden. The conversation begins with the difficulty of convincing asymptomatic patients of their true risk, including addressing feelings of confusion or guilt about their diagnosis, and explaining that genetic vulnerability can place individuals at high risk even at cholesterol levels traditionally considered normal. The panel then turns to the clinical approach for patients whose LDL remains well above target despite initial therapy, with one panelist describing a stepwise strategy that begins with the maximum tolerated statin dose before assessing how far the patient remains from their goal. For patients still significantly above target, the discussion favors prompt escalation to more potent LDL-lowering agents rather than a prolonged sequential approach.

The panelists outline the range of available combination options, including oral therapies and injectable PCSK9 inhibitors offered on biweekly or twice-yearly schedules, emphasizing that treatment selection should center on patient preference and the likelihood of reaching goal efficiently. The panel acknowledges widespread concerns driven by social media around high-intensity statin dosing, noting that a submaximal dose often represents the most practical starting point before adding a complementary agent. The episode closes with a candid discussion of cost and access barriers, recognizing that while prices have declined and access has improved, the administrative burden of securing advanced therapies remains a persistent challenge not only in the United States but globally.

In the next episode, 'Driving Patient Engagement in ASCVD,' panelists will continue their discussion on ASCVD and highlight how clinicians can leverage coronary calcium scoring, personalized risk visualization, and compelling patient communication strategies to overcome treatment resistance and close the gap between guideline-recommended LDL goals and real-world outcomes.